Two PhD students from Sydney have helped restore the sharp vision of the world’s most powerful space observatory without ever leaving the ground. Louis Desdoigts, now a postdoctoral researcher at Leiden University in the Netherlands, and his…
The Japanese carmaker Nissan is to team up with its Chinese electric vehicle rival BYD in an attempt to offset their carbon emissions and avoid EU penalties for 2025, it has confirmed.
It is part of a wider offsetting scheme the EU has sanctioned for the car industry that could help manufacturers of combustion engine cars head off an estimated £13bn in fines.
Nissan said in a statement: “Nissan has formed a pool with BYD for its CO2 fleet emissions in Europe for the 2025 calendar year. The scope of the agreement covers passenger vehicles within EU markets and will contribute to Nissan’s commitment towards zero emissions in a sustainable way, while continuing to support the EU’s 2050 decarbonisation target.”
It added that it had entered into the agreement to “ensure the business is better able to comply with EU regulations and continue the transition towards our own goal of zero emissions”.
Chinese exports of EVs to the EU are already posing an existential crisis to the European car industry but are now, like Tesla, helping traditional car firms meet their decarbonisation targets courtesy of an EU regulation that in effect allows car firms to “pool” emissions.
The EU has already extended the period for compliance with emissions rules from one year to three years, fuelling fears this will further delay the already slow take-up of EVs in the EU, particularly in southern Europe, but also in key states such as France and Germany.
Fredrik Eklund, responsible for carbon credits trading at the Chinese-owned Swedish brand Polestar, which only makes electric vehicles, said: “It risks delaying the transition from legacy cars to EVs. We are already seeing car manufacturers pushing at the 2027 expiry date, but from our point of view and from the point of view of society, we really don’t want to delay this.”
Under the rules, car manufacturers have to meet emissions targets of 93.6g of CO2 per kilometre.
But under the car pooling arrangement, car manufacturers can pay electric car companies to use their zero emissions record to average out the pollution from sales of their combustion engine cars to avoid fines.
The industry in the past has said the 2025 emissions targets could have led to as much as €15bn (£13.03bn) in fines.
The latest car pooling agreement, confirmed by Nissan, mirrors that of other companies who have teamed up with other big name electric car brands including Tesla and Polestar.
skip past newsletter promotion
after newsletter promotion
Polestar has a pooling arrangement with Mercedes-Benz, Volvo and Smart cars, while Tesla’s zero emissions record is being mopped up by Toyota, Ford, Mazda, Alfa Romeo and Suzuki.
The price car companies are paying EV firms to offset their emissions remains confidential. But in January it was reported that carbon credit sales accounted for almost 3% of Tesla’s $72bn (£54bn) total revenue in the first nine months of last year – just over £1.6bn.
The car industry is now fighting for a softening of the EU’s 2035 target for banning the sale of new combustion engine cars, arguing that the public is still not prepared to make the switch in sufficient numbers, citing lack of infrastructure in southern and central Europe as part of the problem.
How to vote for World Athletics Out of Stadium Athlete of the Year 2025
Fans can vote for their Women’s and Men’s Out of Stadium Athlete of the Year on World Athletics’ social media pages, with each individual ‘like’ on Facebook or Instagram and…
Newton K, Strasser A, Kayagaki N, Dixit VM. Cell death. Cell. 2024;187(2):235–56. https://doi.org/10.1016/j.cell.2023.11.044.
Article
PubMed
Google Scholar
Green DR, Victor B. The pantheon of the fallen: why are there so many forms of cell death? Trends Cell Biol. 2012;22(11):555–6. https://doi.org/10.1016/j.tcb.2012.08.008.
Article
PubMed
PubMed Central
Google Scholar
Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72. https://doi.org/10.1016/j.cell.2012.03.042.
Article
PubMed
PubMed Central
Google Scholar
Bannai S, Kitamura E. Transport interaction of L-cystine and L-glutamate in human diploid fibroblasts in culture. J Biol Chem. 1980;255(6):2372–6.
Article
PubMed
Google Scholar
Fotiadis D, Kanai Y, Palacín M. The SLC3 and SLC7 families of amino acid transporters. Mol Aspects Med. 2013;34(2–3):139–58. https://doi.org/10.1016/j.mam.2012.10.007.
Article
PubMed
Google Scholar
Koppula P, Zhang Y, Zhuang L, Gan B. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun (Lond). 2018;38(1):12. https://doi.org/10.1186/s40880-018-0288-x.
Article
PubMed
Google Scholar
Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12(1):34. https://doi.org/10.1186/s13045-019-0720-y.
Article
PubMed
PubMed Central
Google Scholar
Liu J, Xia X, Huang P, xCT:. A critical molecule that links cancer metabolism to redox signaling. Mol Ther. 2020;28(11):2358–66. https://doi.org/10.1016/j.ymthe.2020.08.021.
Article
PubMed
PubMed Central
Google Scholar
Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12(8):599–620. https://doi.org/10.1007/s13238-020-00789-5.
Article
PubMed
Google Scholar
Liu X, Nie L, Zhang Y, et al. Actin cytoskeleton vulnerability to disulfide stress mediates Disulfidptosis. Nat Cell Biol. 2023;25(3):404–14. https://doi.org/10.1038/s41556-023-01091-2.
Article
PubMed
PubMed Central
Google Scholar
Lee N, Park SJ, Lange M, et al. Selenium reduction of ubiquinone via SQOR suppresses ferroptosis. Nat Metab. 2024;6(2):343–58. https://doi.org/10.1038/s42255-024-00974-4.
Article
PubMed
PubMed Central
Google Scholar
Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266–82. https://doi.org/10.1038/s41580-020-00324-8.
Article
PubMed
PubMed Central
Google Scholar
Lin Q, Zhou H, Zeng J, et al. Bioactive polysaccharides mediate ferroptosis to modulate tumor immunotherapy. Int J Biol Macromol. 2024. https://doi.org/10.1016/j.ijbiomac.2024.135147.
Article
PubMed
Google Scholar
Mao C, Wang M, Zhuang L, Gan B. Metabolic cell death in cancer: ferroptosis, cuproptosis, disulfidptosis, and beyond. Protein Cell. 2024;15(9):642–60. https://doi.org/10.1093/procel/pwae003.
Article
PubMed
PubMed Central
Google Scholar
Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18(5):280–96. https://doi.org/10.1038/s41571-020-00462-0.
Article
PubMed
Google Scholar
Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31(2):107–25. https://doi.org/10.1038/s41422-020-00441-1.
Article
PubMed
Google Scholar
Tong X, Tang R, Xiao M, et al. Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and Cuproptosis research. J Hematol Oncol. 2022;15(1):174. https://doi.org/10.1186/s13045-022-01392-3.
Article
PubMed
PubMed Central
Google Scholar
Lang X, Green MD, Wang W, et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 2019;9(12):1673–85. https://doi.org/10.1158/2159-8290.CD-19-0338.
Article
PubMed
PubMed Central
Google Scholar
Li Y, Yan J, Zhao Q, Zhang Y, Zhang Y. ATF3 promotes ferroptosis in sorafenib-induced cardiotoxicity by suppressing Slc7a11 expression. Front Pharmacol. 2022;13:904314. https://doi.org/10.3389/fphar.2022.904314.
Article
PubMed
PubMed Central
Google Scholar
Bassi MT, Gasol E, Manzoni M, et al. Identification and characterisation of human xCT that co-expresses, with 4F2 heavy chain, the amino acid transport activity system Xc-. Pflugers Arch. 2001;442(2):286–96. https://doi.org/10.1007/s004240100537.
Article
PubMed
Google Scholar
Bridges CC, Kekuda R, Wang H, et al. Structure, function, and regulation of human cystine/glutamate transporter in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2001;42(1):47–54.
PubMed
Google Scholar
Kim JY, Kanai Y, Chairoungdua A, et al. Human cystine/glutamate transporter: cDNA cloning and upregulation by oxidative stress in glioma cells. Biochim Biophys Acta. 2001;1512(2):335–44.
Article
PubMed
Google Scholar
Sato H, Tamba M, Kuriyama-Matsumura K, Okuno S, Bannai S. Molecular cloning and expression of human xCT, the light chain of amino acid transport system Xc-. Antioxid Redox Signal. 2000;2(4):665–71. https://doi.org/10.1089/ars.2000.2.4-665.
Article
PubMed
Google Scholar
Li S, Lu Z, Sun R, et al. The role of SLC7A11 in cancer: friend or foe? Cancers (Basel). 2022;14(13):3059. https://doi.org/10.3390/cancers14133059.
Article
PubMed
Google Scholar
Yang J, Zhou Y, Xie S, et al. Metformin induces ferroptosis by inhibiting ufmylation of SLC7A11 in breast cancer. J Exp Clin Cancer Res. 2021;40(1):206. https://doi.org/10.1186/s13046-021-02012-7.
Article
PubMed
PubMed Central
Google Scholar
Badgley MA, Kremer DM, Maurer HC, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science. 2020;368(6486):85–9. https://doi.org/10.1126/science.aaw9872.
Article
PubMed
PubMed Central
Google Scholar
Hong T, Lei G, Chen X, et al. PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer. Redox Biol. 2021;42:101928. https://doi.org/10.1016/j.redox.2021.101928.
Article
PubMed
PubMed Central
Google Scholar
Park JW, Kilic O, Deo M, et al. CIC reduces xCT/SLC7A11 expression and glutamate release in glioma. Acta Neuropathol Commun. 2023;11(1):13. https://doi.org/10.1186/s40478-023-01507-y.
Article
PubMed
PubMed Central
Google Scholar
Long Y, Tao H, Karachi A, et al. Dysregulation of glutamate transport enhances Treg function that promotes VEGF blockade resistance in glioblastoma. Cancer Res. 2020;80(3):499–509. https://doi.org/10.1158/0008-5472.CAN-19-1577.
Article
PubMed
Google Scholar
Yuan L, Li S, Chen Q, et al. EBV infection-induced GPX4 promotes chemoresistance and tumor progression in nasopharyngeal carcinoma. Cell Death Differ. 2022;29(8):1513–27. https://doi.org/10.1038/s41418-022-00939-8.
Article
PubMed
PubMed Central
Google Scholar
Combs JA, DeNicola GM. The non-essential amino acid cysteine becomes essential for tumor proliferation and survival. Cancers (Basel). 2019;11(5):678. https://doi.org/10.3390/cancers11050678.
Article
PubMed
Google Scholar
Carlisle AE, Lee N, Matthew-Onabanjo AN, et al. Selenium detoxification is required for cancer-cell survival. Nat Metab. 2020;2(7):603–11. https://doi.org/10.1038/s42255-020-0224-7.
Article
PubMed
PubMed Central
Google Scholar
Lee N, Carlisle AE, Kim D. Examining xCT-mediated selenium uptake and Selenoprotein production capacity in cells. Methods Enzymol. 2022;662:1–24. https://doi.org/10.1016/bs.mie.2021.10.002.
Article
PubMed
Google Scholar
Goji T, Takahara K, Negishi M, Katoh H. Cystine uptake through the cystine/glutamate antiporter xCT triggers glioblastoma cell death under glucose deprivation. J Biol Chem. 2017;292(48):19721–32. https://doi.org/10.1074/jbc.M117.814392.
Article
PubMed
PubMed Central
Google Scholar
Timmerman LA, Holton T, Yuneva M, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013;24(4):450–65. https://doi.org/10.1016/j.ccr.2013.08.020.
Article
PubMed
PubMed Central
Google Scholar
Shin CS, Mishra P, Watrous JD, et al. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility. Nat Commun. 2017;8:15074. https://doi.org/10.1038/ncomms15074.
Article
PubMed
PubMed Central
Google Scholar
Romero R, Sayin VI, Davidson SM, et al. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med. 2017;23(11):1362–8. https://doi.org/10.1038/nm.4407.
Article
PubMed
PubMed Central
Google Scholar
Bannai S. Induction of cystine and glutamate transport activity in human fibroblasts by diethyl maleate and other electrophilic agents. J Biol Chem. 1984;259(4):2435–40.
Article
PubMed
Google Scholar
Bannai S, Kitamura E. Adaptive enhancement of cystine and glutamate uptake in human diploid fibroblasts in culture. Biochim Biophys Acta. 1982;721(1):1–10. https://doi.org/10.1016/0167-4889(82)90017-9.
Article
PubMed
Google Scholar
Bannai S, Sato H, Ishii T, Taketani S. Enhancement of glutathione levels in mouse peritoneal macrophages by sodium arsenite, cadmium chloride and glucose/glucose oxidase. Biochim Biophys Acta. 1991;1092(2):175–9. https://doi.org/10.1016/0167-4889(91)90153-o.
Article
PubMed
Google Scholar
Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The integrated stress response. EMBO Rep. 2016;17(10):1374–95. https://doi.org/10.15252/embr.201642195.
Article
PubMed
PubMed Central
Google Scholar
Ye P, Mimura J, Okada T, et al. Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition. Mol Cell Biol. 2014;34(18):3421–34. https://doi.org/10.1128/MCB.00221-14.
Article
PubMed
PubMed Central
Google Scholar
Ye Y, Chen A, Li L, et al. Repression of the antiporter SLC7A11/glutathione/glutathione peroxidase 4 axis drives ferroptosis of vascular smooth muscle cells to facilitate vascular calcification. Kidney Int. 2022;102(6):1259–75. https://doi.org/10.1016/j.kint.2022.07.034.
Article
PubMed
Google Scholar
Wang L, Liu Y, Du T, et al. ATF3 promotes erastin-induced ferroptosis by suppressing system Xc. Cell Death Differ. 2020;27(2):662–75. https://doi.org/10.1038/s41418-019-0380-z.
Article
PubMed
Google Scholar
Zhao X, Chen C, Qiu H, et al. The landscape of ATF3 in tumors: metabolism, expression regulation, therapy approach, and open concerns. Pharmacol Res. 2025;214:107666. https://doi.org/10.1016/j.phrs.2025.107666.
Article
PubMed
Google Scholar
Wang Y, Yang L, Zhang X, et al. Epigenetic regulation of ferroptosis by H2B monoubiquitination and p53. EMBO Rep. 2019;20(7):e47563. https://doi.org/10.15252/embr.201847563.
Article
PubMed
PubMed Central
Google Scholar
Zhang Y, Koppula P, Gan B. Regulation of H2A ubiquitination and SLC7A11 expression by BAP1 and PRC1. Cell Cycle. 2019;18(8):773–83. https://doi.org/10.1080/15384101.2019.1597506.
Article
PubMed
PubMed Central
Google Scholar
Tsuchihashi K, Okazaki S, Ohmura M, et al. The EGF receptor promotes the malignant potential of glioma by regulating amino acid transport system xc(-). Cancer Res. 2016;76(10):2954–63. https://doi.org/10.1158/0008-5472.CAN-15-2121.
Article
PubMed
PubMed Central
Google Scholar
Liu L, He J, Sun G, et al. The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma. Clin Transl Med. 2022;12(5):e778. https://doi.org/10.1002/ctm2.778.
Article
PubMed
PubMed Central
Google Scholar
Zhu Y, Zhang C, Huang M, Lin J, Fan X, Ni T. TRIM26 induces ferroptosis to inhibit hepatic stellate cell activation and mitigate liver fibrosis through mediating SLC7A11 ubiquitination. Front Cell Dev Biol. 2021;9:644901. https://doi.org/10.3389/fcell.2021.644901.
Article
PubMed
PubMed Central
Google Scholar
Li S, Lu Z, Sun R, et al. The role of SLC7A11 in cancer: friend or foe? Cancers (Basel). 2022;14(13):3059. https://doi.org/10.3390/cancers14133059.
Article
PubMed
Google Scholar
Ishimoto T, Nagano O, Yae T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011;19(3):387–400. https://doi.org/10.1016/j.ccr.2011.01.038.
Article
PubMed
Google Scholar
Gan W, Dai X, Dai X, et al. LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control. Nat Cell Biol. 2020;22(2):246–56. https://doi.org/10.1038/s41556-020-0463-6.
Article
PubMed
PubMed Central
Google Scholar
Zhang W, Feng J, Ni Y, et al. The role of SLC7A11 in diabetic wound healing: novel insights and new therapeutic strategies. Front Immunol. 2024;15:1467531. https://doi.org/10.3389/fimmu.2024.1467531.
Article
PubMed
PubMed Central
Google Scholar
Gu Y, Albuquerque CP, Braas D, et al. mTORC2 regulates amino acid metabolism in cancer by phosphorylation of the Cystine-Glutamate antiporter xCT. Mol Cell. 2017;67(1):128–e1387. https://doi.org/10.1016/j.molcel.2017.05.030.
Article
PubMed
PubMed Central
Google Scholar
Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273–85. https://doi.org/10.1016/j.cell.2017.09.021.
Kagan VE, Mao G, Qu F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13(1):81–90. https://doi.org/10.1038/nchembio.2238.
Article
PubMed
Google Scholar
Chu B, Kon N, Chen D, et al. ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat Cell Biol. 2019;21(5):579–91. https://doi.org/10.1038/s41556-019-0305-6.
Article
PubMed
PubMed Central
Google Scholar
Jiang L, Kon N, Li T, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520(7545):57–62. https://doi.org/10.1038/nature14344.
Article
PubMed
PubMed Central
Google Scholar
Jennis M, Kung CP, Basu S, et al. An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev. 2016;30(8):918–30. https://doi.org/10.1101/gad.275891.115.
Article
PubMed
PubMed Central
Google Scholar
Zhang Y, Shi J, Liu X, et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol. 2018;20(10):1181–92. https://doi.org/10.1038/s41556-018-0178-0.
Article
PubMed
PubMed Central
Google Scholar
Liu T, Jiang L, Tavana O, Gu W. The deubiquitylase OTUB1 mediates ferroptosis via stabilization of SLC7A11. Cancer Res. 2019;79(8):1913–24. https://doi.org/10.1158/0008-5472.CAN-18-3037.
Article
PubMed
PubMed Central
Google Scholar
Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021;32(9):1101–10. https://doi.org/10.1016/j.annonc.2021.06.001.
Article
PubMed
Google Scholar
Xiong HJ, Yu HQ, Zhang J, et al. Elevated FBXL6 activates both wild-type KRAS and mutant KRASG12D and drives HCC tumorigenesis via the ERK/mTOR/PRELID2/ROS axis in mice. Mil Med Res. 2023;10(1):68. https://doi.org/10.1186/s40779-023-00501-8.
Article
PubMed
PubMed Central
Google Scholar
Mueller S, Engleitner T, Maresch R, et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature. 2018;554(7690):62–8. https://doi.org/10.1038/nature25459.
Article
PubMed
PubMed Central
Google Scholar
Hu K, Li K, Lv J, et al. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. J Clin Invest. 2020;130(4):1752–66. https://doi.org/10.1172/JCI124049.
Article
PubMed
PubMed Central
Google Scholar
Lim JKM, Delaidelli A, Minaker SW, et al. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proc Natl Acad Sci U S A. 2019;116(19):9433–42. https://doi.org/10.1073/pnas.1821323116.
Article
PubMed
PubMed Central
Google Scholar
Chen X, Li J, Kang R, Klionsky DJ, Tang D. Ferroptosis: machinery and regulation. Autophagy. 2021;17(9):2054–81. https://doi.org/10.1080/15548627.2020.1810918.
Article
PubMed
Google Scholar
Wang W, Green M, Choi JE, et al. CD8 + T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270–4. https://doi.org/10.1038/s41586-019-1170-y.
Article
PubMed
PubMed Central
Google Scholar
Kim DH, Kim WD, Kim SK, Moon DH, Lee SJ. TGF-β1-mediated repression of SLC7A11 drives vulnerability to GPX4 Inhibition in hepatocellular carcinoma cells. Cell Death Dis. 2020;11(5):406. https://doi.org/10.1038/s41419-020-2618-6.
Article
PubMed
PubMed Central
Google Scholar
Dai E, Han L, Liu J, et al. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy. 2020;16(11):2069–83. https://doi.org/10.1080/15548627.2020.1714209.
Article
PubMed
PubMed Central
Google Scholar
Bi G, Liang J, Zhao M, et al. MiR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways. Mol Ther. 2022;28:366–86. https://doi.org/10.1016/j.omtn.2022.03.020.
Article
Google Scholar
Qin K, Zhang F, Wang H, et al. CircRNA circSnx12 confers cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axis. BMB Rep. 2023;56(2):184–9. https://doi.org/10.5483/BMBRep.2022-0175.
Article
PubMed
PubMed Central
Google Scholar
Sun C, Liu P, Pei L, Zhao M, Huang Y. Propofol inhibits proliferation and augments the anti-tumor effect of doxorubicin and paclitaxel partly through promoting ferroptosis in triple-negative breast cancer cells. Front Oncol. 2022;12:837974. https://doi.org/10.3389/fonc.2022.837974.
Article
PubMed
PubMed Central
Google Scholar
Yadav P, Sharma P, Sundaram S, Venkatraman G, Bera AK, Karunagaran D. SLC7A11/ xCT is a target of miR-5096 and its restoration partially rescues miR-5096-mediated ferroptosis and anti-tumor effects in human breast cancer cells. Cancer Lett. 2021;522:211–24. https://doi.org/10.1016/j.canlet.2021.09.033.
Article
PubMed
Google Scholar
Chen X, Kang R, Kroemer G, Tang D. Ferroptosis in infection, inflammation, and immunity. J Exp Med. 2021;218(6):e20210518. https://doi.org/10.1084/jem.20210518.
Article
PubMed
PubMed Central
Google Scholar
Mi T, Kong X, Chen M, Guo P, He D. Inducing disulfidptosis in tumors: potential pathways and significance. MedComm (2020). 2024;5(11):e791. https://doi.org/10.1002/mco2.791
Yan Y, Teng H, Hang Q, et al. Slc7a11 expression level dictates differential responses to oxidative stress in cancer cells. Nat Commun. 2023;14(1):3673. https://doi.org/10.1038/s41467-023-39401-9.
Article
PubMed
PubMed Central
Google Scholar
Joly JH, Delfarah A, Phung PS, Parrish S, Graham NA. A synthetic lethal drug combination mimics glucose deprivation-induced cancer cell death in the presence of glucose. J Biol Chem. 2020;295(5):1350–65. https://doi.org/10.1074/jbc.RA119.011471.
Article
PubMed
Google Scholar
Liu T, Ren Y, Wang Q, et al. Exploring the role of the disulfidptosis-related gene SLC7A11 in adrenocortical carcinoma: implications for prognosis, immune infiltration, and therapeutic strategies. Cancer Cell Int. 2023;23(1):259. https://doi.org/10.1186/s12935-023-03091-6.
Article
PubMed
PubMed Central
Google Scholar
Zhao D, Meng Y, Dian Y, et al. Molecular landmarks of tumor disulfidptosis across cancer types to promote disulfidptosis-target therapy. Redox Biol. 2023;68:102966. https://doi.org/10.1016/j.redox.2023.102966.
Article
PubMed
PubMed Central
Google Scholar
Li J, Yu T, Sun J, et al. Integrated analysis of disulfidptosis-related immune genes signature to boost the efficacy of prognostic prediction in gastric cancer. Cancer Cell Int. 2024;24(1):112. https://doi.org/10.1186/s12935-024-03294-5.
Article
PubMed
PubMed Central
Google Scholar
Xia Q, Yan Q, Wang Z, et al. Disulfidptosis-associated lncRNAs predict breast cancer subtypes. Sci Rep. 2023;13(1):16268. https://doi.org/10.1038/s41598-023-43414-1.
Article
PubMed
PubMed Central
Google Scholar
Liu L, Liu J, Lyu Q, et al. Disulfidptosis-associated lncRNAs index predicts prognosis and chemotherapy drugs sensitivity in cervical cancer. Sci Rep. 2023;13(1):12470. https://doi.org/10.1038/s41598-023-39669-3.
Article
PubMed
PubMed Central
Google Scholar
Korangath P, Teo WW, Sadik H, et al. Targeting glutamine metabolism in breast cancer with aminooxyacetate. Clin Cancer Res. 2015;21(14):3263–73. https://doi.org/10.1158/1078-0432.CCR-14-1200.
Article
PubMed
PubMed Central
Google Scholar
Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21(2):141-162. doi:10.1038/s41573-021-00339-6
Shao N, Qiu H, Liu J, et al. Targeting lipid metabolism of macrophages: a new strategy for tumor therapy. J Adv Res. 2025;68:99–114. https://doi.org/10.1016/j.jare.2024.02.009.
Article
PubMed
Google Scholar
Zhao X, Zhao J, Li D, et al. Akkermansia muciniphila: a potential target and pending issues for oncotherapy. Pharmacol Res. 2023;196:106916. https://doi.org/10.1016/j.phrs.2023.106916.
Article
PubMed
Google Scholar
Liu X, Zhuang L, Gan B. Disulfidptosis: disulfide stress-induced cell death. Trends Cell Biol. 2024;34(4):327–37. https://doi.org/10.1016/j.tcb.2023.07.009.
Article
PubMed
Google Scholar
Qiu H, Shao N, Liu J, et al. Amino acid metabolism in tumor: new shine in the fog? Clin Nutr. 2023;42(8):1521–30. https://doi.org/10.1016/j.clnu.2023.06.011.
Article
PubMed
Google Scholar
Liu J, Shao N, Qiu H, et al. Intestinal microbiota: A Bridge between intermittent fasting and tumors. Biomed Pharmacother. 2023;167:115484. https://doi.org/10.1016/j.biopha.2023.115484.
An 18-year-old male patient, a Moroccan international student in China, presented to the emergency department of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, with a chief complaint of persistent upper…
We all age, and for decades, science has been looking for a way to slow that clock. Much of that research is now focused on epigenetics—a system of “software” that runs on our genetic “hardware,” telling genes when to turn on and off.…
SUSPECTED LOUVRE THIEVES ARRESTED. Two suspects have been detained in connection with the theft of jewels, including pieces once belonging to Emperor Napoleon III and Empress Eugénie, from the Louvre on October 19….
